The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Bayer (BAYZF) (BAYRY) says elinzanetant, its experimental therapy for hot flashes, reached the main goals in a late-stage ...

(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating the ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...

EET Orion's collaboration partner Bayer submits application in China for third indication of darolutamide Orion's collaboration ...

Market Growth: Understand the significant growth trajectory of the Contraceptive Implants segment, which is expected to reach US$9.8 Billion by 2030 with a CAGR of a 6.3%. The Spinal Implants segment ...